BRIEF published on 11/27/2025 at 10:10, 9 months 15 days ago Global Leaders Convene for Paris Conference on Global Challenges Global Challenges Energy Transition Sustainable Finance Economic Leaders Conference Of Paris
BRIEF published on 11/27/2025 at 10:10, 9 months 15 days ago Les dirigeants mondiaux se réunissent à Paris pour la Conférence sur les défis mondiaux Transition Énergétique Finance Durable Défis Mondiaux Conférence De Paris Dirigeants Économiques
BRIEF published on 11/27/2025 at 10:10, 9 months 15 days ago Farizon Expands European Operations with New Spare Parts Warehouse Sustainable Transportation Strategic Cooperation European Logistics Farizon Spare Parts Warehouse
BRIEF published on 11/27/2025 at 10:10, 9 months 15 days ago Farizon étend ses activités européennes avec un nouvel entrepôt de pièces détachées Transport Durable Coopération Stratégique Logistique Européenne Farizon Entrepôt De Pièces Détachées
BRIEF published on 11/27/2025 at 10:10, 9 months 15 days ago EMA Grants Orphan Drug Designation to Kedrion's Treatment for ACP Biopharmaceutical Innovation Kedrion Orphan Drug EMA Approval Iron Metabolism
BRIEF published on 11/27/2025 at 10:10, 9 months 15 days ago L'EMA accorde la désignation de médicament orphelin au traitement de Kedrion contre l'ACP Innovation Biopharmaceutique Kedrion Médicament Orphelin Approbation De L'EMA Métabolisme Du Fer
BRIEF published on 11/27/2025 at 10:05, 9 months 15 days ago Asklepios Group Reports Solid Third Quarter and Secures New Financing Financial Strategy Healthcare Investment Asklepios Group Patient Growth Schuldschein Loan
BRIEF published on 11/27/2025 at 10:05, 9 months 15 days ago Le groupe Asklepios annonce un solide troisième trimestre et obtient un nouveau financement. Stratégie Financière Groupe Asklépios Investissement Dans Le Secteur De La Santé Prêt Schuldschein Croissance Du Patient
BRIEF published on 11/27/2025 at 09:50, 9 months 15 days ago Protagenic Therapeutics Faces Nasdaq Non-Compliance Notice Delisting NASDAQ Non-compliance Stockholders' Equity Quarterly Report Delay Protagenic Therapeutics
BRIEF published on 11/27/2025 at 09:50, 9 months 15 days ago Protagenic Therapeutics fait l'objet d'un avis de non-conformité du Nasdaq Capitaux Propres Radiation Non-conformité Du Nasdaq Thérapeutiques Protagéniques Retard Dans La Publication Du Rapport Trimestriel
Published on 09/12/2026 at 02:35, 10 hours 39 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 14 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 9 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 15 hours 49 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 14 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 5 hours 43 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 14 hours 59 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 3 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 29 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 18 hours 58 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 17 hours ago Availability of the 2026 Interim Financial Report
